The Filing Desk

Carlsmed vs TriSalus Life Sciences

Carlsmed CARL · TriSalus Life Sciences TLSI · Health Care Equipment

Carlsmed reported revenue of $50 million in fiscal 2025, about the same as TriSalus Life Sciences' $45 million in fiscal 2025. Carlsmed's revenue grew 85.9% in its latest year, and TriSalus Life Sciences' grew 53.4%. Carlsmed had an operating margin of -60.5%, against -59.7% at TriSalus Life Sciences. Free cash flow was −$30 million at Carlsmed and −$19 million at TriSalus Life Sciences.

Side by side

CarlsmedTriSalus Life Sciences
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$50M$45M
Revenue growth85.9%53.4%
Revenue growth a year, last 5 years——
Gross margin75.3%84.6%
Operating margin−60.5%−59.7%
Net margin−58.7%−86.9%
Free cash flow−$30M−$19M
Free cash flow margin−58.6%−41.9%
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count249.7%49.6%
Last close$17.22$2.17
P/E at the last close——
Insider trades, last 12 monthssold $2.6 millionbought $3.7 million, sold $137,130
Piotroski F-score—3 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
CarlsmedTriSalus Life Sciences
Operating margin
Percent of revenue
CarlsmedTriSalus Life Sciences
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
CarlsmedTriSalus Life Sciences

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Carlsmed and TriSalus Life Sciences pages.